Evaxion Biotech A/S Stock Scheduled to Reverse Split on Monday, January 13th (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock is going to reverse split on the morning of Monday, January 13th. The 1-5 reverse split was announced on Monday, December 30th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 10th.

Evaxion Biotech A/S Stock Down 11.7 %

Shares of Evaxion Biotech A/S stock opened at $0.85 on Wednesday. Evaxion Biotech A/S has a fifty-two week low of $0.83 and a fifty-two week high of $13.61. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The firm has a market cap of $4.96 million, a P/E ratio of -2.92 and a beta of -0.39. The business has a 50-day moving average price of $1.69 and a 200 day moving average price of $2.51.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The business had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. On average, sell-side analysts forecast that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Armistice Capital LLC raised its holdings in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 392,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Armistice Capital LLC owned approximately 7.24% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent quarter. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.